scholarly journals Effect of Antihypertensive Therapy on Blood Rheology in Patients with Essential Hypertension

2005 ◽  
Vol 33 (2) ◽  
pp. 170-177 ◽  
Author(s):  
H Sumino ◽  
M Nara ◽  
K Seki ◽  
T Takahashi ◽  
T Kanda ◽  
...  

Hypertension is an important risk factor for cardiovascular disease, and antihypertensive drugs can decrease the occurrence of such events in hypertensive patients. This study compared the rheological properties of blood in 22 untreated hypertensive patients, 42 patients taking antihypertensive drugs and 74 normotensive subjects. Using a microchannel method, the whole blood passage time was measured and blood movement was observed with a microscope connected to an image display unit. The blood passage time in untreated hypertensive patients was significantly higher than in treated hypertensive patients or normotensive subjects, but was similar in the latter two groups. Microscopic observations showed that platelet aggregation and leucocyte adhesion were increased in untreated hypertensive patients, resulting in poor flow, while blood samples from treated hypertensive patients and normotensive subjects passed smoothly through the microchannels. These rheological differences could contribute to the decrease in cardiovascular disease seen when hypertensive patients are treated effectively.

2016 ◽  
Vol 12 (1) ◽  
pp. 28-32
Author(s):  
Mst Nasrin Nahar ◽  
Shelina Begum ◽  
Sultana Ferdousi ◽  
Sharmeen Sultana ◽  
Zinia Parveen ◽  
...  

Introduction: Essential hypertension is associated with altered pulmonary function. Antihypertensive medication and lung function are also associated. Amlodipine (calcium channel blocker) and Atenolol (beta blocker) are commonly used antihypertensive drugs. Objective: To evaluate the effects of antihypertensive drugs on lung function status in patients with essential hypertension. Materials and Methods: This prospective observational study was carried out in the Department of Physiology of Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka, from July 2012 to June 2013 on 100 newly diagnosed essential hypertensive patients. Based on prescribed treatment, these study subjects were divided into two groups - B1 and B2. B1 included 50 patients who received amlodipine 5mg daily and B2 included 50 patients who received atenolol 50mg daily. Lung function tests were done in both B1 and B2 groups before taking medication, after 3 months of medication and after 6 months of medication. For assessing lung function status, Forced Vital Capacity (FVC), Forced Expiratory Volume in 1st second (FEV1) and Peak Expiratory Flow Rate (PEFR) were measured with a computer based Spirometer. Age, sex and BMI matched 50 apparently healthy normotensive subjects were also studied as control (group A). Data were compared among subjects of different groups. For statistical analysis independent sample‘t’ test and paired sample‘t’ test were performed. Results: Mean FVC, FEV1 and PEFR were significantly lower in newly diagnosed hypertensive patients in comparison with that of healthy normotensive subjects. Mean FVC, FEV1 and PEFR were found significantly higher in the group taking amlodipine for 6 months when compared to newly diagnosed hypertensive patients but lower than those of controls. In addition mean FVC and FEV1 were found significantly lower in the group taking atenolol for 6 months when compared to newly diagnosed hypertensive patients and those of controls. Conclusion: Reduced lung function occurs in newly diagnosed essential hypertensive patients which improve by treatment with amlodipine but decreases after treatment with atenolol. Journal of Armed Forces Medical College Bangladesh Vol.12(1) 2016: 28-32


2012 ◽  
Vol 35 (11) ◽  
pp. 1087-1092 ◽  
Author(s):  
Tatsuo Kawai ◽  
Mitsuru Ohishi ◽  
Yasushi Takeya ◽  
Miyuki Onishi ◽  
Norihisa Ito ◽  
...  

2021 ◽  
Vol 135 (13) ◽  
pp. 1609-1625
Author(s):  
Aristeidis Sionakidis ◽  
Linsay McCallum ◽  
Sandosh Padmanabhan

Abstract Cardiovascular disease remains the primary cause of mortality globally, being responsible for an estimated 17 million deaths every year. Cancer is the second leading cause of death on a global level with roughly 9 million deaths per year being attributed to neoplasms. The two share multiple common risk factors such as obesity, poor physical exercise, older age, smoking and there exists rare monogenic hypertension syndromes. Hypertension is the most important risk factor for cardiovascular disease and affects more than a billion people worldwide and may also be a risk factor for the development of certain types of cancer (e.g. renal cell carcinoma (RCC)). The interaction space of the two conditions becomes more complicated when the well-described hypertensive effect of certain antineoplastic drugs is considered along with the extensive amount of literature on the association of different classes of antihypertensive drugs with cancer risk/prevention. The cardiovascular risks associated with antineoplastic treatment calls for efficient management of relative adverse events and the development of practical strategies for efficient decision-making in the clinic. Pharmacogenetic interactions between cancer treatment and hypertension-related genes is not to be ruled out, but the evidence is not still ample to be incorporated in clinical practice. Precision Medicine has the potential to bridge the gap of knowledge regarding the full spectrum of interactions between cancer and hypertension (and cardiovascular disease) and provide novel solutions through the emerging field of cardio-oncology. In this review, we aimed to examine the bidirectional associations between cancer and hypertension including pharmacotherapy.


2021 ◽  
pp. 23-26
Author(s):  
Balendra Shekhar Deepankar ◽  
Saurabh Singh Thakur ◽  
Vimlesh Patidar

Introduction: Hypertension is a common health problem in developed countries and a major risk factor for cardiovascular diseases. Hypertension exhibits an iceberg phenomenon where unknown morbidity exceeds the known morbidity. Genetic and environmental factors are also reported to play a key role in hypertension, 90% of which are better classied as idiopathic. The cause of cardiovascular diseases in the hypertensive patient is blood pressure raised which is present chronically however the cause of elevated BP are different. In adults, 90% of hypertension cases are of essential hypertension .The Remaining 10% of hypertension cases with chronically elevated BP accounts for secondary cause. In hypertensive patient, the risk of cardiovascular disease is increases in men and women. Hypertension and diabetes mellitus are among the most common chronic non-communicable diseases and multifactorial disorders affecting both developed and developing countries and occur at a higher prevalence in the older age group and result from both genetic and environmental etiological factors. The aim of Study of Cardiovascular Abnormality in the Hypertension Patient. Methods: A prospective observational study consists of 95 cases of hypertension is undertaken to study the cardiovascular abnormality by ECG and ECHO. The study will be conducted on patients suffering from hypertension. A written informed consent will be taken from all the patients who are included in study group. All the data of the patients will be recorded on a pretested Performa. Preliminary data like name, age, sex, occupation, residence, date will be recorded. Detailed lipid prole study will be done to nd the correlation in patients with hypertension. All data will be statistically analyzed. Results: Out of 95 cases in the study group, 51 were female cases and 44 were males, 31 cases (7th decade), 40 cases (6th decade), 14 cases (5th decade), 8 cases(4th decade), 2 cases (< 3rd decade). Abnormal ECG changes which constitutes 85 patients, ST elevation was present in 12 patients and T-wave inversion was present in 47 patients, followed by 16 patients were shows left ventricular hypertrophy, 8 cases of cardiomyopathy which shows low voltage complexes. Coronary artery disease was predominant nding in the patients of hypertensive cardiovascular disease which was present in 54 cases out of 95 cases, of which 31 were male patients and 23 were female patients. CAD in hypertension (57%), the incidence of CAD was more in elderly and other abnormalities in hypertensive patients were left ventricular hypertrophy(11.6%), heart failure{due to cardiomyopathy(8.2%) and CAD} and valvular heart disease(4.2%). Conclusion: Cardiovascular abnormality in hypertensive patients encompasses a broad spectrum including coronary artery disease, asymptomatic LVH (either a concentric or an eccentric pattern) and clinical heart failure (with either a preserved or a reduced LVEF) stroke, heart failure, cardiomyopathy, arrhythmia, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis. Elderly age, smoking habits, chronic alcoholism and long standing history of DM have emerged as important risk factor for cardiovascular disease in hypertensive patients.


1982 ◽  
Vol 63 (s8) ◽  
pp. 41s-43s ◽  
Author(s):  
W. Zidek ◽  
H. Vetter ◽  
K.-G. Dorst ◽  
H. Zumkley ◽  
H. Losse

1. The intracellular Na+ and Ca2+ activity and Na+ concentration were measured in erythrocytes of normotensive subjects, with and without a familial disposition to hypertension, in essential hypertensive patients with and without a family history of hypertension, and in patients with secondary hypertension. 2. In normotensive subjects without a genetic trait of hypertension intracellular Na+ activity and concentration were 7.00 ± 1.38 mmol/l and 5.67 ± 0.95 mmol/l respectively. The intracellular Ca2+ activity was 4.82 ± 4.49 μmol/l. In normotensive subjects with a familial hypertensive disposition intracellular Na+ activity and concentration were 9.74 ± 1.43 mmol/l (P < 0.01) and 6.63 ± 0.88 mmol/l (P < 0.05). Intracellular Ca2+ was 9.59 ± 9.71 μmol/l (P < 0.05). 3. Essential hypertensive patients without a familial genetic trait had an elevated intracellular Na+ activity (8.35 ± 2.08 mmol/l, P < 0.05). Intracellular Na+ concentration was 6.64 ± 0.79 mmol/l (P < 0.05). The intracellular Ca2+ activity was markedly elevated to 25.33 ± 19.03 μmol/l (P < 0.01). The essential hypertensive patients with a familial disposition had an elevated intracellular Na+ activity (17.19 ± 4.37 mmol/l, P < 0.001) and Ca2+ activity (32.8 ± 32.51 μmol/l, P < 0.01). The intracellular Na+ concentration was 6.25 ± 1.23 mmol/l. 4. The results indicate that in essential hypertension intracellular Na+ activity is increased, particularly in patients with a familial disposition for hypertension. Intracellular Ca2+ is increased in essential hypertension whether or not there was a family disposition to hypertension.


2007 ◽  
Vol 20 (6) ◽  
pp. 599-607 ◽  
Author(s):  
D WEYCKER ◽  
G NICHOLS ◽  
M OKEEFFEROSETTI ◽  
J EDELSBERG ◽  
Z KHAN ◽  
...  

1981 ◽  
Vol 60 (5) ◽  
pp. 483-489 ◽  
Author(s):  
W. Kiowski ◽  
F. R. Bühler ◽  
P. Vanbrummelen ◽  
F. W. Amann

1. Plasma noradrenaline concentrations and blood pressure were measured in 45 patients with essential hypertension and 34 matched normotensive subjects. Plasma noradrenaline was similar in both groups, but in the hypertensive patients plasma noradrenaline correlated with blood pressure. 2. The increase in forearm flow in response to an intra-arterial infusion of phentolamine was determined in 12 of the hypertensive and 14 of the normotensive subjects to assess the α-adrenoceptor-mediated component of vascular resistance. Although the dilator response to phentolamine was similar in both groups, in the hypertensive patients it was correlated with the control plasma noradrenaline (r = 0.83, P<0.01) as well as the height of mean blood pressure (r = 0.73, P<0.01). 3. These results suggest that in hypertensive patients plasma noradrenaline can be a marker for both sympathetic activity and the α-adrenoceptor-mediated component of vascular resistance.


1977 ◽  
Vol 52 (3) ◽  
pp. 319-323 ◽  
Author(s):  
R. F. Bing ◽  
J. Harlow ◽  
A. J. Smith ◽  
M. M. Townshend

1. The 24 h urinary excretion of adrenaline, noradrenaline, normetadrenaline, metadrenaline and vanilloylmandelic acid has been compared in 17 male normotensive subjects and 25 age-matched male hypertensive patients studied under similar in-patient conditions. 2. 24 h urinary metadrenaline was significantly lower in the hypertensive patients. With this exception, no significant differences were found between the two groups when the total 24 h excretion of free catecholamines and their metabolites was analysed. 3. Diurnal variation in free catecholamine excretion was found in both normotensive and hypertensive subjects. There was no corresponding variation in metabolite excretion. 4. No correlation could be established between systolic or diastolic blood pressure and the amounts of the catecholamines or their metabolites in the urine of either group. 5. The results are considered in the light of recent work demonstrating high plasma catecholamine concentrations in hypertension. They lend no support to the concept that excessive circulating catecholamines are responsible for the elevated blood pressure in essential hypertension.


1976 ◽  
Vol 51 (s3) ◽  
pp. 211s-213s
Author(s):  
M. Ulrych ◽  
Z. Ulrych

1. Relationships between labelled albumin disappearance rate (LADR), plasma volume, blood volume, plasma renin activity (PRA) and blood pressure (BP) were studied in normotensive control subjects and patients with hypertension of different aetiology and severity. In essential hypertensive patients without complications an inverse linear relationship was found between blood pressure and plasma or blood volume. 2. Very close inverse correlations were found between LADR and PRA in both normotensive subjects and patients with uncomplicated essential hypertension. LADR appears to be an excellent reference standard for PRA. 3. It is postulated that LADR mainly reflects the relation between circulating fluid and vascular capacitance tone. LADR is increased in hypertension and blood volume may still be inappropriately high.


Sign in / Sign up

Export Citation Format

Share Document